## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type R	Responses	s)																	
1. Name and Address of Reporting Person* Rice William G.				2. Issuer Name and Ticker or Trading Symbol Aptose Biosciences Inc. [APTO]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_ Director 10% Owner								
(Last) (First) (Middle) C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105					3. Date of Earliest Transaction (Month/Day/Year) 03/10/2020							X Officer (give title below) Other (specify below)  Chair, President & CEO							
TORONTO, A6 M2J 4R3					4. If Amendment, Date Original Filed(Month/Day/Year) 03/12/2020							6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting Person  _Form filed by More than One Reporting Person							
(City) (State) (Zip)					Table I - Non-Derivative Securities Acqu							ired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	•			(Instr. 8)		(A) or Disposed of		f (D) Beneficia Reported		unt of Securities ially Owned Following d Transaction(s)		Form:	p of Be	7. Nature of Indirect Beneficial		
				(Mont	h/Day/Y	(ear)		ode	V	Amou	ınt	(A) or (D)	Price	(Instr. 3 a	and 4)		Direct (D) or Indirect (I) (Instr. 4)		vnership str. 4)
Common Shares 03/		03/10/2020			A	Α		300,0	00	A	\$ 0	463,014			D				
								quire	the f	orm di	spla of, o	nys a o	curre eficia	ently valid	OMB con	spond unle trol numbe			
(Instr. 3) Prid Der	enversion Exercise ice of rivative curity	3. Transaction Date (Month/Day/	n 3A. Deemed Execution Da any	4. Transaction Code Year) (Instr. 8)		5.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. T Am Und Sec	Citle and ount of derlying urities str. 3 and	t of Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owner Form Deriva Securi Direct or Ind	of tive ty: (D) frect	Beneficia Ownershi (Instr. 4)			
					Code	V	(A)	(D)	Date Exer	e rcisable		oiration e	Titl	or Number of Shares					
Reporti	ng O	wners																	

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Rice William G. C/O APTOSE BIOSCIENCES INC. 251 CONSUMERS ROAD, SUITE 1105 TORONTO, A6 M2J 4R3	X		Chair, President & CEO				

## **Signatures**

/s/ Janet Clennett as attorney-in-fact for William G. Rice	05/07/2020		
**Signature of Reporting Person	Date		

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) Restricted stock units previously granted with original vesting date of June 10, 2020, which shall now vest on July 10, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.